PDF-This guidance document is being distributed for comment purposes only PDF document

15028dftdoc 072716 Additional copies are available from Office of Communications Division of Drug Information Center for Drug Evaluation and Research Food and Drug

Upload by carla
Published on 2022-08-24

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/940845" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "This guidance document is being distribu..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

This guidance document is being distributed for comment purposes only: Transcript

PDF-This guidance document is being distributed for comment purposes only PDF document

Presentation Embed Code

Download Presentation

This guidance document is being distributed for comment purposes only: Transcript

Related Contents

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE

Informed Consent Information Sheet Guidance for IRBs Clinical Investigators and Sponsors

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits

Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs

Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment

Guidance for Industry Contract Manufacturing Arrangements for Drugs Quality Agreements

Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of

Guidance for Industry Distributing Scientific and Medical Publications on Unapproved New

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT

Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE

Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance

Guidance for Industry Chronic Fatigue Syndrome Myalgic Encephalomyelitis Developing Drug

Guidance for Industry Applications for Premarket Review of New Tobacco Products DRAFT